In an article published in Nature in 2016, they used the platform to test a new type of kidney cancer drug, HIF-2α inhibitors, recently approved by the FDA. KCP researchers have previously deployed this resource to advance precision medicine. “This resource also helps provide more precise and personalized treatment to patients,” said Vanina Tcheuyap, MS, co-lead author and research associate at the Brugarolas laboratory who oversees the platform. “This platform goes beyond conventional models to become models that closely mimic the range of human kidney cancers,” said Kimryn Rathmell, MD, Ph.D., former chair of the Cancer Research Program Integration Group Kidney Fund from the Department of Defense, the largest funder of kidney cancer research in the world.
The majority of tumor models have been characterized by next-generation sequencing and have been found to have both frequent and rarer cancer mutations. “Tumors in mice also preserve responsiveness to treating kidney cancer in patients,” he added. Tumors in mice are more similar to the donor patient than two tumors from two different patients,” said co-lead author Roy Elias, MD, former researcher from the laboratory of James Brugarolas, MD, Ph.D., professor of internal medicine, division of hematology and oncology, and director of the KCP. “It’s like they remember where they came from. Patients’ tumors can be identified by a unique gene expression signature, which tumors in mice maintain. KCP researchers have previously shown that tumors in mice preserved characteristics of cancer in patients. Over a decade, KCP researchers transplanted tumors from 926 patients of various ethnic origins at UT Southwestern Medical Center and its affiliate Parkland Memorial Hospital into mice, generating a library of 172 tumor graft lines.īy transplanting tumor samples from intact, preservative-free patients taken in the operating room directly into mouse kidneys within an hour or two of surgery, KCP researchers are able to generate tumors closely mirroring the human kidney cancer. The development of drugs for less common types has been limited by a lack of animal models suitable for preclinical studies.ĭescribed in an article published this week in Cell reports, the KCP platform includes a wide range of models for the scientific community.
Most of the drugs approved by the Food and Drug Administration were developed to treat clear cell renal cell carcinoma, the most common form of kidney cancer, but there are more than a dozen other types. Despite the development of new drugs to treat kidney cancer, it remains largely incurable when it is metastatic. Kidney cancer is the eighth most commonly diagnosed cancer in the United States. Simmons Comprehensive Cancer Center at UT Southwestern’s Kidney Cancer Program (KCP) features the largest and most diverse catalog of kidney cancer tumor models.
Funded by a National Cancer Institute (NCI) Specialized Program of Research Excellence (SPORE) award, the Harold C.
0 kommentar(er)
